Cikkek nyilvánosan hozzáférhető megbízással - MOHAMAD NAVABTovábbi információ
Sehol sem hozzáférhető: 5
Chronic inflammatory disorders and accelerated atherosclerosis: chronic kidney disease
K D. Navab, S Y. Hama, S Safarpour, G P. Hough, L Vakili, S T. Reddy, ...
Current Pharmaceutical Design 17 (1), 17-20, 2011
Megbízások: US National Institutes of Health
Treatment with an apolipoprotein A-1 mimetic peptide in combination with pravastatin inhibits collagen-induced arthritis
C Charles-Schoeman, ML Banquerigo, S Hama, M Navab, GS Park, ...
Clinical immunology 127 (2), 234-244, 2008
Megbízások: US National Institutes of Health
Searching for a successful HDL-based treatment strategy
ST Reddy, M Navab, GM Anantharamaiah, AM Fogelman
Biochimica et Biophysica Acta (BBA)-Molecular and Cell Biology of Lipids …, 2014
Megbízások: US National Institutes of Health
ApoA-I mimetic peptides: a review of the present status
M Navab, ST Reddy, D Meriwether, SI Fogelman, AM Fogelman
Apolipoprotein Mimetics in the Management of Human Disease, 15-27, 2015
Megbízások: US National Institutes of Health
Apolipoprotein AI Mimetic Peptides in Mouse Models of Cancer
R Farias-Eisner, F Su, GM Anantharamahiah, M Navab, AM Fogelman, ...
Apolipoprotein Mimetics in the Management of Human Disease, 55-62, 2015
Megbízások: US National Institutes of Health
Valahol hozzáférhető: 71
HDL and cardiovascular disease: atherogenic and atheroprotective mechanisms
M Navab, ST Reddy, BJ Van Lenten, AM Fogelman
Nature Reviews Cardiology 8 (4), 222-232, 2011
Megbízások: US National Institutes of Health
Safety, pharmacokinetics, and pharmacodynamics of oral apoA-I mimetic peptide D-4F in high-risk cardiovascular patients
LAT Bloedon, R Dunbar, D Duffy, P Pinell-Salles, R Norris, BJ DeGroot, ...
Journal of lipid research 49 (6), 1344-1352, 2008
Megbízások: US National Institutes of Health
NOTCH1 is a mechanosensor in adult arteries
JJ Mack, TS Mosqueiro, BJ Archer, WM Jones, H Sunshine, GC Faas, ...
Nature communications 8 (1), 1620, 2017
Megbízások: US National Institutes of Health
The role of dysfunctional HDL in atherosclerosis
M Navab, ST Reddy, BJ Van Lenten, GM Anantharamaiah, AM Fogelman
Journal of lipid research 50, S145-S149, 2009
Megbízások: US National Institutes of Health
Apolipoprotein AI (apoA-I) and apoA-I mimetic peptides inhibit tumor development in a mouse model of ovarian cancer
F Su, KR Kozak, S Imaizumi, F Gao, MW Amneus, V Grijalva, C Ng, ...
Proceedings of the National Academy of Sciences 107 (46), 19997-20002, 2010
Megbízások: US National Institutes of Health
Anti-inflammatory and antioxidant properties of HDLs are impaired in type 2 diabetes
C Morgantini, A Natali, B Boldrini, S Imaizumi, M Navab, AM Fogelman, ...
Diabetes 60 (10), 2617-2623, 2011
Megbízások: US National Institutes of Health
Anti-inflammatory apoA-I-mimetic peptides bind oxidized lipids with much higher affinity than human apoA-I
BJ Van Lenten, AC Wagner, CL Jung, P Ruchala, AJ Waring, RI Lehrer, ...
Journal of lipid research 49 (11), 2302-2311, 2008
Megbízások: US National Institutes of Health
Paraoxonase 2 deficiency alters mitochondrial function and exacerbates the development of atherosclerosis
A Devarajan, N Bourquard, S Hama, M Navab, VR Grijalva, S Morvardi, ...
Antioxidants & redox signaling 14 (3), 341-351, 2011
Megbízások: US National Institutes of Health
Host-derived oxidized phospholipids and HDL regulate innate immunity in human leprosy
D Cruz, AD Watson, CS Miller, D Montoya, MT Ochoa, PA Sieling, ...
The Journal of clinical investigation 118 (8), 2917-2928, 2008
Megbízások: US National Institutes of Health, Howard Hughes Medical Institute
Treatment of patients with cardiovascular disease with L-4F, an apo-A1 mimetic, did not improve select biomarkers of HDL function [S]
CE Watson, N Weissbach, L Kjems, S Ayalasomayajula, Y Zhang, ...
Journal of lipid research 52 (2), 361-373, 2011
Megbízások: US National Institutes of Health
Diesel exhaust induces systemic lipid peroxidation and development of dysfunctional pro-oxidant and pro-inflammatory high-density lipoprotein
F Yin, A Lawal, J Ricks, JR Fox, T Larson, M Navab, AM Fogelman, ...
Arteriosclerosis, thrombosis, and vascular biology 33 (6), 1153-1161, 2013
Megbízások: US National Institutes of Health
HDL as a biomarker, potential therapeutic target, and therapy
M Navab, GM Anantharamaiah, ST Reddy, BJ Van Lenten, AM Fogelman
Diabetes 58 (12), 2711-2717, 2009
Megbízások: US National Institutes of Health
In vitro stimulation of HDL anti-inflammatory activity and inhibition of LDL pro-inflammatory activity in the plasma of patients with end-stage renal disease by an apoA-1 …
ND Vaziri, H Moradi, MV Pahl, AM Fogelman, M Navab
Kidney international 76 (4), 437-444, 2009
Megbízások: US National Institutes of Health
Structure and function of HDL mimetics
M Navab, I Shechter, GM Anantharamaiah, ST Reddy, BJ Van Lenten, ...
Arteriosclerosis, thrombosis, and vascular biology 30 (2), 164-168, 2010
Megbízások: US National Institutes of Health
Hemoglobin and its scavenger protein haptoglobin associate with apoA-1-containing particles and influence the inflammatory properties and function of high density lipoprotein
J Watanabe, V Grijalva, S Hama, K Barbour, FG Berger, M Navab, ...
Journal of Biological Chemistry 284 (27), 18292-18301, 2009
Megbízások: US National Institutes of Health
A publikációs és a finanszírozási adatokat számítógépes program határozza meg, automatikusan.